

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Omicron variant in Qatar

Nature Medicine

27, 2136-2143

DOI: [10.1038/s41591-021-01583-4](https://doi.org/10.1038/s41591-021-01583-4)

Citation Report

#	ARTICLE	IF	CITATIONS
4	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
6	National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan. <i>Surgery Today</i> , 2022, 52, 763-773.	0.7	7
7	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. <i>Lancet, The</i> , 2021, 398, 1407-1416.	6.3	978
8	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	15.2	450
9	COVID-19 vaccine boosters: What do we know so far?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100959.	0.6	17
10	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
11	Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. <i>Vaccines</i> , 2021, 9, 1286.	2.1	117
12	Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan. <i>Journal of Global Health</i> , 2021, 11, 05025.	1.2	12
13	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
14	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. <i>Global Epidemiology</i> , 2021, 3, 100068.	0.6	30
16	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
18	COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly. <i>Vaccines</i> , 2021, 9, 1299.	2.1	58
19	Previous COVID-19 Infection and Antibody Levels After Vaccination. <i>Frontiers in Public Health</i> , 2021, 9, 778243.	1.3	69
20	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
21	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
24	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
25	The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. <i>Inflammopharmacology</i> , 2022, 30, 149-157.	1.9	3
27	Update on COVID-19 vaccination in pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2022, 26, e14235.	0.5	9

#	ARTICLE	IF	CITATIONS
28	COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhône-Alpes region (France): An ecological study. <i>Vaccine</i> , 2022, 40, 695-700.	1.7	1
29	Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. <i>Journal of Health Economics</i> , 2022, 82, 102589.	1.3	23
31	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
32	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
35	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
36	The effectiveness of mRNA vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 2269-2274.	2.5	14
37	Intrauterine Fetal Demise in the Third Trimester of Pregnancy Associated With Mild Infection With the SARS-CoV-2 Delta Variant Without Protection From Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 225, 748-753.	1.9	18
38	Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 116, 114-121.	1.5	2
39	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 21, 100389.	1.3	16
40	County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100191.	1.5	13
41	A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. <i>EMBO Molecular Medicine</i> , 2022, 14, e15298.	3.3	23
42	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	30
44	Natural Products and Nanotechnology Against Coronavirus Disease 2019. <i>Frontiers in Chemistry</i> , 2022, 10, 819969.	1.8	8
45	A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 962-964.	0.8	1
46	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 585-592.	3.0	50
47	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
48	A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	94
49	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194

#	ARTICLE	IF	CITATIONS
50	Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e617-e622.	2.9	10
51	SARS-CoV-2 Omicron variant: Characteristics and prevention. <i>MedComm</i> , 2021, 2, 838-845.	3.1	364
52	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
53	Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 75, e827-e837.	2.9	9
57	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. <i>Microbial Biotechnology</i> , 2022, 15, 721-737.	2.0	41
58	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ</i> , The, 2021, 375, e068848.	3.0	180
59	A simple and rapid method to assay SARS-CoV-2 RNA based on a primer exchange reaction. <i>Chemical Communications</i> , 2022, 58, 4484-4487.	2.2	11
60	Reconstruction of a large-scale outbreak of SARS-CoV-2 infection in Iceland informs vaccination strategies. <i>Clinical Microbiology and Infection</i> , 2022, 28, 852-858.	2.8	11
62	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
64	Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals. <i>Vaccines</i> , 2022, 10, 332.	2.1	10
65	Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February–September 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 673-679.	1.5	4
66	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 277.	2.1	15
67	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 285.	2.1	13
68	Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-28.	0.9	7
69	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	6.0	177
70	VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 435.	2.1	8
71	Factors Related to Non-compliance With Non-pharmaceutical Interventions to Mitigate the Spread of SARS-CoV-2: Results From a Survey in the Swiss General Adult Population. <i>Frontiers in Public Health</i> , 2022, 10, 828584.	1.3	2
72	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4

#	ARTICLE	IF	CITATIONS
73	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
74	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1032.	3.8	57
77	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311
78	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
79	Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. <i>Frontiers in Immunology</i> , 2022, 13, 850987.	2.2	35
80	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e579-e584.	2.9	17
81	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1042-1049.	15.2	61
83	Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. <i>MBio</i> , 2022, 13, e0361721.	1.8	67
84	The fine-scale associations between socioeconomic status, density, functionality, and spread of COVID-19 within a high-density city. <i>BMC Infectious Diseases</i> , 2022, 22, 274.	1.3	12
85	mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2022, 226, 797-807.	1.9	25
86	COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1002-1010.	4.6	192
87	Modeling COVID-19 dynamic using a two-strain model with vaccination. <i>Chaos, Solitons and Fractals</i> , 2022, 157, 111927.	2.5	26
88	Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China*. <i>Emerging Microbes and Infections</i> , 2022, 11, 1205-1214.	3.0	5
90	Vaccination against COVID-19 in Ukraine. <i>Safety of Vaccines. Ukraïns'kij Å¾urnal Medicini BÅologÅ Ta Sportu</i> , 2021, 6, 200-206.	0.0	0
93	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Vaccines</i> , 2022, 10, 23.	2.1	37
96	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
97	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311.	5.8	100
98	Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects. <i>Infection</i> , 2022, , 1.	2.3	11

#	ARTICLE	IF	CITATIONS
99	Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). <i>Clinical Infectious Diseases</i> , 2022, 75, 1971-1979.	2.9	12
100	Detailed characterization of hospitalized patients infected with the Omicron variant of SARS-CoV-2. <i>Journal of Internal Medicine</i> , 2022, 292, 385-387.	2.7	3
101	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
103	Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron. <i>Biochemistry Research International</i> , 2022, 2022, 1-7.	1.5	3
104	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission. <i>Epidemics</i> , 2022, 39, 100567.	1.5	2
106	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. <i>Journal of Infectious Diseases</i> , 2022, 226, 1551-1555.	1.9	4
107	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
108	Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine. <i>Aids</i> , 2022, 36, 1255-1264.	1.0	13
109	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
110	An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination.. <i>International Journal of Infectious Diseases</i> , 2022, 121, 98-101.	1.5	4
111	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. <i>Translational Research</i> , 2022, 248, 11-21.	2.2	13
112	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
113	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93
114	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
115	Impact of national Covid-19 vaccination Campaign, South Korea. <i>Vaccine</i> , 2022, 40, 3670-3675.	1.7	21
116	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. <i>New England Journal of Medicine</i> , 2022, 386, 2097-2111.	13.9	147
117	Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. <i>Nature Communications</i> , 2022, 13, 2494.	5.8	22
118	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	3

#	ARTICLE	IF	CITATIONS
119	The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35054.	1.2	3
120	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. <i>PLoS ONE</i> , 2022, 17, e0267824.	1.1	15
121	SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC). <i>Scientific Reports</i> , 2022, 12, 8074.	1.6	5
122	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
123	Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 4234-4245.	2.5	14
125	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <i>Lancet Respiratory Medicine</i> , 2022, 10, 749-760.	5.2	65
127	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
128	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. <i>Immunity</i> , 2022, 55, 1316-1326.e4.	6.6	38
129	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16
131	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
132	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
133	Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study. <i>Vaccines</i> , 2022, 10, 822.	2.1	2
134	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	25
135	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
137	Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
138	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
139	COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
140	Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults. <i>Journal of Clinical Virology</i> , 2022, 152, 105193.	1.6	12

#	ARTICLE	IF	CITATIONS
141	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
142	Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 209.	1.1	4
144	Antigenicity of genomic epidemiology concerning viral evolution and vaccine efficacy for SARS-CoV-2- A review. , 2022, , .		0
145	Hesitancy towards the Third Dose of COVID-19 Vaccine among the Younger Generation in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7041.	1.2	6
146	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). <i>Vaccines</i> , 2022, 10, 984.	2.1	10
147	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
148	Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. <i>BMC Public Health</i> , 2022, 22, .	1.2	5
149	Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance. <i>Environmental Technology and Innovation</i> , 2022, 27, 102775.	3.0	17
150	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
151	SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS TYPE 2 OMICRON VARIANT OUTBREAK IN INDIA: TIME TO ALERT. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 1-8.	0.3	0
152	Contemporary Concise Review 2021: <sc>COVID</sc> and other respiratory infections. <i>Respirology</i> , 0, , .	1.3	1
153	Schools under mandatory testing can mitigate the spread of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
155	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
156	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
157	Comparative COVID-19 Vaccine Effectiveness over Time in Veterans. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	15
158	Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus. <i>International Journal of Biological Macromolecules</i> , 2022, 213, 1007-1017.	3.6	3
159	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in [®] , in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. <i>EClinicalMedicine</i> , 2022, 50, 101526.	3.2	20
160	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59

#	ARTICLE	IF	CITATIONS
161	<i>Pseudomonas aeruginosa</i> : pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	239
162	Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1629-1635.	2.8	12
163	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. <i>PLoS ONE</i> , 2022, 17, e0270801.	1.1	18
164	COVID-19 in children: epidemic issues and candidate vaccines. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	2
166	Prognostic impact of delta variant on COVID-19 outcomes: a retrospective cohort study. <i>Journal of Infection</i> , 2022, 33, 291-298.	0.0	1
169	SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge in Denver, Colorado, and San Diego, California, January to April 2021. <i>Vaccine</i> , 2022, 40, 4845-4855.	1.7	2
171	Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
172	COVID-19 and plasma cells: Is there long-lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
174	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
175	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
176	Discovering COVID-19 state sustainable policies for mitigating and ending the pandemic. <i>Cities</i> , 2022, 130, 103865.	2.7	7
177	Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
178	Clinical outcomes of Pfizer/BioNTech COVID-19 vaccine in children and adolescents: A systematic review. <i>Health Science Reports</i> , 2022, 5, .	0.6	1
179	COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1014-1025.	1.5	3
180	Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. <i>JAMA Network Open</i> , 2022, 5, e2223917.	2.8	19
181	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
183	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
184	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13

#	ARTICLE	IF	CITATIONS
185	Parental decision and intent towards COVID-19 vaccination in children with asthma: an econometric analysis. <i>BMC Public Health</i> , 2022, 22, .	1.2	9
187	Surface Inactivation of Highly Mutated SARS-CoV-2 Variants of Concern: Alpha, Delta, and Omicron. <i>Biomacromolecules</i> , 2022, 23, 3960-3967.	2.6	1
188	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
190	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
191	Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study. <i>Vaccine</i> , 2022, 40, 5675-5682.	1.7	2
192	Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	6
194	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	5.8	12
195	SARS-CoV-2-specific T _H cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> , 2022, 55, 1764-1778.	6.6	63
196	COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?. <i>Journal of Global Health</i> , 0, 12, .	1.2	0
197	Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1572.	2.1	5
199	Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. <i>International Journal of Infectious Diseases</i> , 2022, 124, 1-10.	1.5	12
200	A six-month study of anti-SARS-CoV-2 BNT162b2 mRNA vaccination: A comparative analysis of essential trace elements and anti-RBD IgG sera levels. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 74, 127079.	1.5	1
201	Global asymptotic stability, extinction and ergodic stationary distribution in a stochastic model for dual variants of SARS-CoV-2. <i>Mathematics and Computers in Simulation</i> , 2023, 204, 302-336.	2.4	16
202	Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	7
203	SARS-CoV-2 Infections in Vaccinated and Unvaccinated Populations in Camp Lemonnier, Djibouti, from April 2020 to January 2022. <i>Viruses</i> , 2022, 14, 1918.	1.5	0
204	RNA therapeutics: updates and future potential. <i>Science China Life Sciences</i> , 2023, 66, 12-30.	2.3	31
205	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. <i>PLoS Pathogens</i> , 2022, 18, e1010802.	2.1	27
206	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7

#	ARTICLE	IF	CITATIONS
207	Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
208	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44
210	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
211	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
212	A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
213	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
214	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
215	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. <i>Npj Vaccines</i> , 2022, 7, .	2.9	3
216	Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
218	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. <i>Cell Reports</i> , 2022, 41, 111544.	2.9	17
219	Estimating vaccine effectiveness against SARS-CoV-2 infection, hospitalization and death from ecologic data in Costa Rica. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
220	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
222	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
223	Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study. <i>Respiratory Research</i> , 2022, 23, .	1.4	13
224	Effectiveness of Covid-19 vaccines (Covishield™ and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. <i>PLoS ONE</i> , 2022, 17, e0276759.	1.1	4
225	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
226	Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. <i>Military Medical Research</i> , 2022, 9, .	1.9	13
227	Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1471-1485.	2.4	11

#	ARTICLE	IF	CITATIONS
228	Modeling and numerical analysis of a fractional order model for dual variants of SARS-CoV-2. AEJ - Alexandria Engineering Journal, 2023, 65, 427-442.	3.4	13
229	Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants. IScience, 2022, 25, 105438.	1.9	6
230	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
231	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	3
232	Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population. Vaccines, 2022, 10, 1781.	2.1	17
233	Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transplantation and Cellular Therapy, 2023, 29, 10-18.	0.6	5
234	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. New England Journal of Medicine, 2022, 387, 1865-1876.	13.9	37
235	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. Human Vaccines and Immunotherapeutics, 0, , .	1.4	2
237	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. Vaccines, 2022, 10, 1924.	2.1	8
238	Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. BMJ Open, 2022, 12, e063919.	0.8	8
240	COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. Eurosurveillance, 2022, 27, .	3.9	6
241	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe, The, 2022, 3, e944-e955.	3.4	34
243	A review of COVID vaccines: success against a moving target. British Medical Bulletin, 2022, 144, 12-44.	2.7	5
244	Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study. BMC Infectious Diseases, 2022, 22, .	1.3	0
245	SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. Seminars in Hematology, 2022, 59, 192-197.	1.8	5
246	Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative caseâ€“control study. Lancet Regional Health - Europe, The, 2023, 25, 100552.	3.0	11
247	IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7
249	Nanovaccines against Viral Infectious Diseases. Pharmaceutics, 2022, 14, 2554.	2.0	6

#	ARTICLE	IF	CITATIONS
250	Enhanced Vaccine Effectiveness during the Delta Phase of the COVID-19 Pandemic in the Medicare Population Supports a Multilayered Prevention Approach. <i>Biology</i> , 2022, 11, 1700.	1.3	1
251	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	2
252	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
254	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299.	0.2	0
255	Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation. <i>Vaccines</i> , 2022, 10, 2069.	2.1	2
256	Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants. <i>Heliyon</i> , 2022, 8, e12594.	1.4	1
257	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
258	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	3
259	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
260	Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies. <i>PLoS ONE</i> , 2022, 17, e0278624.	1.1	3
261	Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. <i>IScience</i> , 2022, 25, 105649.	1.9	7
262	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
263	Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. <i>PLoS Pathogens</i> , 2022, 18, e1011065.	2.1	10
264	Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design caseâ€“control study. <i>PLoS Medicine</i> , 2023, 20, e1004156.	3.9	5
265	COVID-19 vaccine hesitancy between family decision-makers and non-decision-makers among college teachers. <i>Annals of Medicine</i> , 2023, 55, 292-304.	1.5	2
266	Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar. <i>Nature Communications</i> , 2023, 14, .	5.8	4
267	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
268	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2

#	ARTICLE	IF	CITATIONS
269	Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series. <i>Journal of Immunological Methods</i> , 2023, 513, 113410.	0.6	1
270	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
271	COVID-19 Risk Compensation? Examining Vaccination Uptake among Recovered and Classification of Breakthrough Cases. <i>Healthcare (Switzerland)</i> , 2023, 11, 58.	1.0	2
272	COVID-19 Booster Vaccine Hesitancy among Hemodialysis Patients in Saudi Arabia Using the Health Belief Model: A Multi-Centre Experience. <i>Vaccines</i> , 2023, 11, 95.	2.1	2
273	Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. <i>Journal of Immunology</i> , 2022, 209, 2104-2113.	0.4	8
274	SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	5
275	Precision-engineering of subunit vaccine particles for prevention of infectious diseases. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
276	A vigorous study of fractional order mathematical model for SARS-CoV-2 epidemic with Mittag-Leffler kernel. <i>AEJ - Alexandria Engineering Journal</i> , 2023, 71, 565-579.	3.4	6
277	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2024, 42, 187-194.	0.2	3
278	Deterministic and Fractional-Order Co-Infection Model of Omicron and Delta Variants of Asymptomatic SARS-CoV-2 Carriers. <i>Fractal and Fractional</i> , 2023, 7, 192.	1.6	0
279	Mass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices. <i>Applied Materials Today</i> , 2023, 31, 101754.	2.3	7
280	A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma. <i>International Journal of Hematology</i> , 2023, 117, 900-909.	0.7	1
281	Biomimetic Nanotechnology for SARS-CoV-2 Treatment. <i>Viruses</i> , 2023, 15, 596.	1.5	1
282	Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan. <i>Access Microbiology</i> , 2023, 5, .	0.2	0
283	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
284	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
285	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
286	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5

#	ARTICLE	IF	CITATIONS
287	SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. <i>Nature Communications</i> , 2023, 14, .	5.8	9
288	Effectiveness and adverse effects of astrazeneca and pfizer COVID-19 vaccines among medical students in Oman: A comparative study. <i>Biomedical and Biotechnology Research Journal</i> , 2023, 7, 101.	0.3	1
289	Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A caseâ€“control study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	6
290	The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
291	The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. <i>Cell</i> , 2023, 186, 2392-2409.e21.	13.5	24
292	Immediate and Contributory Causes of Death in Patients Hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	0
293	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. <i>Zoonoses</i> , 2023, 3, .	0.5	1
295	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
296	COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	2
340	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3